Table 3 Tumor outcome information
Authors | Year | Outcome | TB-1 | TB-0 | P-value | HR | HR_LI | HR_UI |
|---|---|---|---|---|---|---|---|---|
C. Du | 2012 | 5-year DFS | 55.6% | 87.5% |  < 0.001 | 1.45 | 0.13 | 15.71 |
M. Huebner | 2012 | 5-year CSS | 73.8% | 88.4% | – | 6.73 | 1.56 | 28.96 |
A. C. Rogers | 2013 | 5-year DFS | 33.3% | 77.5% |  ≤ 0.001 | 3.49 | 0.73 | 16.60 |
5-year CSS | 61.1% | 87.3% | 0.021 | 5.79 | 0.44 | 76.62 | ||
LR | 33% | 10% | 0.012 | – | – | – | ||
DR* | 44% | 15% | 0.007 | – | – | – | ||
5-year CSD | 39% | 13% | 0.01 | 3.51 | 1.03 | 11.93 | ||
J. W. Huh | 2016 | 5-year DFS | – | – | – | 1.109 | 0.593 | 2.073 |
LR | – | – | – | 2.040 | 0.766 | 5.429 | ||
T. Jäger | 2018 | 5-year RFS | 71% | 90% | 0.02 | 3.44 | 1.23 | 9.63 |
5-year OS | 80% | 90% | 0.09 | – | – | – | ||
LR | 7% | 0% | 0.27 | – | – | – | ||
DR | 12% | 2% | 0.03 | – | – | – | ||
M. Swets | 2018 | 5-year DFS | – | – | – | 1.54 | 1.00 | 2.37 |
5-year OS | – | – | – | 1.54 | 1.09 | 3.03 | ||
DR | – | – | – | 1.60 | 1.00 | 2.57 | ||
A. Demir | 2019 | 1-year DFS | 86% | 93% | 0.01 | – | – | – |
3-year DFS | 24% | 61% | 0.01 | – | – | – | ||
J. W. Huh | 2019 | 5-year OS | – | – | – | 1.48 | 0.535 | 4.094 |
I. Trotsyuk | 2019 | 5-year DFSa | 39% | 75% |  < 0.001 | 2.34 | 1.14 | 4.79 |
5-year OSa | 53% | 84% | 0.001 | 2.72 | 1.15 | 6.44 | ||
5-year DFSb | 44% | 87% |  < 0.001 | 4.59 | 1.79 | 11.72 | ||
5-year OSb | 59% | 92% |  < 0.001 | 5.19 | 1.62 | 16.61 | ||
L. Farchoukh | 2021 | 5-year DFS | 39% | 87% | 0.001 | 3.35 | 1.25 | 8.99 |
LR | 4% | 2% | – | – | – | – | ||
DR | 31% | 7% | – | – | – | – | ||
J. K. Shin | 2021 | 5-year DFS | 65.4% | 80.5% |  < 0.001 | 1.665 | 1.108 | 2.504 |
5-year OS | 82.1% | 94.7% |  < 0.001 | 2.102 | 1.111 | 9.979 |